Feasibility of gabapentin as an intervention for neurorecovery after an acute spinal cord injury: Protocol.

ABSTRACT:

Introduction

This protocol is describing the first ever prospective, mock-efficacy, dose exploration trial design testing the feasibility of administering gabapentin in the acute setting as an intervention for neurorecovery. Gabapentin is an FDA-approved medication for treating seizures and postherpetic neuralgia and is used broadly off-label for neuropathic pain management for many conditions, including spinal cord injury. Emerging data suggests that when given early after spinal cord injury onset and in low-medium doses, gabapentin may have properties that promote recovery of neurological function. The objective of this trial is to assess the feasibility of conducting an efficacy trial in which gabapentin is started early after injury, is restricted in its dose, and is not used f

SUBMITTER: Wilson JR 

PROVIDER: S-EPMC9676350 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature